Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT) will release its third-quarter 2021 financial results on November 9, 2021, post-market. A conference call with management to discuss these results will occur at 5:00 p.m. ET. Interested investors can join the call by dialing (833) 360-0946 for domestic and (914) 987-7661 for international participants, using Conference ID: 1968232. The event will also be available via a live and archived webcast on Certara's Investors webpage.
Certara specializes in biosimulation software and technology, assisting over 1,650 clients globally.
Positive
- Certara's biosimulation technology serves over 1,650 clients, indicating strong market demand.
- Upcoming Q3 earnings call scheduled for November 9, 2021, may provide insights for investors.
Negative
- None.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was +3.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 1968232. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.